Thrombolytic therapy in acute myocardial infarction

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Myocardial infarction (MI) poses a significant mortality risk.
• Early reperfusion is crucial for limiting myocardial damage and preserving cardiac function.

Purpose of the Study:

• To review the efficacy and safety of early thrombolytic therapy in acute myocardial infarction.
• To outline optimal treatment strategies and adjunctive therapies.

Main Methods:

• Review of existing clinical trials and guidelines on thrombolytic therapy for MI.
• Analysis of different thrombolytic agents (streptokinase, urokinase, APSAC, rt-PA) and administration routes (IV, intracoronary).

Main Results:

• Thrombolytic therapy reduces hospital mortality by 20-50% and infarct size by 15-30%.
• Optimal timing is early after symptom onset, especially for extensive ischemia.
• Bleeding complications occur in a minority; intracranial bleeding risk is ~0.5%, with no increased CVA risk in some trials.
• Acetylsalicylic acid and heparin are recommended to prevent rethrombosis.

Conclusions:

• Early thrombolytic therapy is a cornerstone in managing acute myocardial infarction.
• Careful patient selection and adjunctive therapies optimize outcomes.
• Further research is needed on late-stage treatment benefits.